Last reviewed · How we verify
AG NPP709syrup
AG NPP709syrup is a ACE inhibitor Small molecule drug developed by Ahn-Gook Pharmaceuticals Co.,Ltd. It is currently in Phase 3 development for Hypertension.
AG NPP709 syrup is a medication that targets the renin-angiotensin system to treat hypertension.
AG NPP709syrup is a treatment being studied for its safety and efficacy in Acute Upper Respiratory Tract Infections and Bronchitis. According to ClinicalTrials.gov, AG NPP709syrup is being evaluated in a therapeutic confirmatory clinical trial.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AG NPP709syrup |
|---|---|
| Sponsor | Ahn-Gook Pharmaceuticals Co.,Ltd |
| Drug class | ACE inhibitor |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
AG NPP709 syrup works by inhibiting the angiotensin-converting enzyme (ACE), which is a key component of the renin-angiotensin system. This leads to decreased levels of angiotensin II, a potent vasoconstrictor, resulting in vasodilation and decreased blood pressure.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
- Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "AG NPP709 Syrup" (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AG NPP709syrup CI brief — competitive landscape report
- AG NPP709syrup updates RSS · CI watch RSS
- Ahn-Gook Pharmaceuticals Co.,Ltd portfolio CI
Frequently asked questions about AG NPP709syrup
What is AG NPP709syrup?
How does AG NPP709syrup work?
What is AG NPP709syrup used for?
Who makes AG NPP709syrup?
What drug class is AG NPP709syrup in?
What development phase is AG NPP709syrup in?
What are the side effects of AG NPP709syrup?
What does AG NPP709syrup target?
Related
- Drug class: All ACE inhibitor drugs
- Target: All drugs targeting ACE
- Manufacturer: Ahn-Gook Pharmaceuticals Co.,Ltd — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing